Overview

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Status:
Active, not recruiting

Trial end date:
2024-06-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in Chinese subjects with metastatic hormone sensitive prostate cancer (mHSPC). The study will be conducted in two phases: Double-Blind treatment phase and open-label phase.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma China, Inc.

Treatments:

Androgens
Ascorbic Acid
Estrogens, Conjugated (USP)
Hormones
Methyltestosterone